candesartan and thromboxane a2

candesartan has been researched along with thromboxane a2 in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's6 (85.71)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
el-Haschimi, K; Epping, P; Ko, Y; Sachinidis, A; Seul, C; Vetter, H1
Casado, S; Farré, J; Gómez, J; Jiménez, A; López-Blaya, A; López-Farré, A; Montón, M; Núñez, A; Sánchez de Miguel, L; Zalba, LR1
Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L1
Casado, S; Gómez, J; Jiménez, A; Lopez-Bloya, A; López-Farré, A; Montón, M; Núñez, A; Rico, L; Sánchez de Miguel, L1
Bassenge, E; Schwemmer, M; Sommer, O1
Casado, S; Gómez, J; Jiménez, A; López-Blaya, A; López-Farré, A; Montón, M; Núñez, A; Uriarte, AC; Velasco, S; Zalba, LR1
Schieffer, B; Schmidt, B1

Reviews

2 review(s) available for candesartan and thromboxane a2

ArticleYear
Angiotensin II AT(1) receptor antagonists and platelet activation.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16 Suppl 1

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Coronary Disease; Coronary Thrombosis; Humans; Losartan; P-Selectin; Platelet Activation; Platelet Aggregation; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Thromboxane; Tetrazoles; Thrombosis; Thromboxane A2; Valine; Valsartan

2001
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
    Journal of medicinal chemistry, 2003, Jun-05, Volume: 46, Issue:12

    Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Growth Hormone; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Models, Molecular; Receptor, Angiotensin, Type 1; Tetrazoles; Thiophenes; Thromboxane A2

2003

Other Studies

5 other study(ies) available for candesartan and thromboxane a2

ArticleYear
Carbocyclic thromboxane A2 enhances the angiotensin II-induced DNA synthesis in smooth muscle cells.
    European journal of pharmacology, 1996, Jun-20, Volume: 307, Issue:1

    Topics: Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cell Division; Cells, Cultured; DNA; Muscle, Smooth, Vascular; Platelet Aggregation Inhibitors; Proto-Oncogene Proteins c-fos; Rats; Rats, Inbred WKY; RNA, Messenger; Tetrazoles; Thromboxane A2; Vasoconstrictor Agents

1996
Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
    Journal of cardiovascular pharmacology, 2000, Volume: 35, Issue:6

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antibodies, Monoclonal; Benzimidazoles; Benzoates; Binding, Competitive; Biphenyl Compounds; Blood Platelets; Dose-Response Relationship, Drug; Humans; Imidazoles; Irbesartan; Losartan; Platelet Activation; Pyridines; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Telmisartan; Tetrazoles; Thromboxane A2; Time Factors; Valine; Valsartan

2000
Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.
    Journal of cardiovascular pharmacology, 2001, Volume: 37, Issue:4

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Platelets; Blood Pressure; Humans; Hypertension; Losartan; P-Selectin; Platelet Activation; Platelet Adhesiveness; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Tetrazoles; Thromboxane A2; Valine; Valsartan

2001
Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling.
    Cardiovascular drugs and therapy, 2001, Volume: 15, Issue:4

    Topics: Angiotensin Receptor Antagonists; Animals; Arachidonic Acids; Benzimidazoles; Biphenyl Compounds; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Imidazoles; Losartan; Phospholipases A; Phospholipases A2; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Thromboxane; Renin-Angiotensin System; Signal Transduction; Tetrazoles; Thromboxane A2

2001
Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2000, Volume: 1, Issue:2

    Topics: Adenosine Diphosphate; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Blood Platelets; Cells, Cultured; Drug Interactions; Humans; Losartan; Male; Platelet Activation; Platelet Aggregation Inhibitors; Receptor, Angiotensin, Type 1; Tetrazoles; Thromboxane A2; Valine; Valsartan

2000